SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-24-027505
Filing Date
2024-02-08
Accepted
2024-02-08 07:00:50
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFM14A d734477ddefm14a.htm DEFM14A 1591029
2 GRAPHIC g734477g09t03.jpg GRAPHIC 28131
3 GRAPHIC g734477g41x01.jpg GRAPHIC 24549
4 GRAPHIC g734477g41x02.jpg GRAPHIC 26380
5 GRAPHIC g734477g59k18.jpg GRAPHIC 32199
6 GRAPHIC g734477g76c08.jpg GRAPHIC 63177
7 GRAPHIC g734477g85d98.jpg GRAPHIC 53488
  Complete submission text file 0001193125-24-027505.txt   1896225
Mailing Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080 (650) 443-7400
Harpoon Therapeutics, Inc. (Filer) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-38800 | Film No.: 24606827
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)